Search for:
  • Sign in
  • Register
  • Reports
  • Interviews
  • Articles
  • Legal & Regulatory
  • Facts & Figures
  • Op-eds
  • Shop
Sunday, November 15, 2026
PharmaBoardroom
Sign In Register
  • Home
  • Country Reports
    • All
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Exclusive interviews
    • All
    • Latest
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Articles
    • All
    • Global
    • Latest
  • Legal & Regulatory
    • All
    • The Pharma Legal Handbook
    • Regulatory, Pricing and Reimbursement
    • Marketing, Manufacturing, Packaging and Labeling
    • Preclinical and Clinical Trials
  • Op-Eds & Contributions
  • InFigures
    • All
    • Rankings
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Library
    • All
    • InFocus
    • InFigures
    • White Papers
  • Media Kit
  • Register
  • About Us
  • Reports
  • Interviews
  • Articles
  • Legal & Regulatory
  • Facts & Figures
  • Op-eds
  • Shop
Peru: Pharma Market Report 2017 Download

Peru

July 2015

See more

Key Market Facts

  • South Korea's record-breaking licensing deals in 2015-2016 — with Hanmi Pharmaceutical and other Korean companies signing multi-billion dollar deals with global pharmaceutical companies — signalled Korea's emergence as a genuine source of pharmaceutical innovation.
  • Peru's pharmaceutical market is served primarily by imports and multinational subsidiaries, with limited domestic manufacturing. Key multinational companies including Pfizer, Novartis, Sanofi, Bayer, and Abbott all maintain Peruvian commercial operations.
  • Regulatory authority: DIGEMID (Directorate General of Medicines, Inputs and Drugs) under the Ministry of Health oversees pharmaceutical regulation and drug approvals in Peru.
  • Peru's universal health insurance coverage has been gradually expanding through SIS (Seguro Integral de Salud) and EsSalud, increasing pharmaceutical expenditure and market size, though coverage remains incomplete compared to regional peers.
  • Peru's pharmaceutical market in 2017 was navigating the political uncertainty following the Odebrecht corruption scandal, which implicated senior government officials and created broader economic uncertainty affecting healthcare investment and pharmaceutical policy.

Legal & Regulatory

report
Buy
Share on Linkedin Share

Sharing Link

or sharing via

WhatsApp Email
Back
PharmaBoardroom

PharmaBoardroom Limited
Evolution House
Iceni Court, Delft Way,
Norwich, NR6 6BB UK

Latest

  • Articles
  • In Conversation
  • Facts & Figures
  • Country Reports
  • Legal & Regulatory
  • InFocus

More

  • About Us
  • Media Kit

Join Us

  • Email Newsletters
  • LinkedIn

Contact

+44 0 207 870 3438

info@pharmaboardroom.com

Legal & Privacy

  • Terms and Conditions
  • Privacy and Cookies policy
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here

logo

Sign in

Forgot password? Register now